March 2, 2018 7:42am

… It happened before, it happens again and it will another time

Oversold equities are today’s happening;  the question is when this downturn will ‘end” itself as I believe the reverberations are not over

 

Tomato juice can neutralize the downturn stench if you add some distilled cereal grains and potatoes that have fermented … just slow breathe through it, it’s Friday

The sector might not bounce but, we surely will …

 

Pre-open indications: 1 BUY and 2 SELLs

 

If you had been subscribing, today’s events would not have been a surprise …

Lower open expected

 

Dow futures are DOWN -0.76% (-186 points) and NASDAQ futures are DOWN -0.75% (-51 points)

 

U.S. stock index futures fell ahead of Friday's open.

Europe markets sharply lower on Trump’s tariff announcement;

While Asian markets sell off after Trump's tariff announcement

 

Issues to be faced at the open: negative open

Data docket: consumer sentiment is due out at 10 a.m. ET. No speeches by the U.S. Federal Reserve are due to take place Friday.

 

 

Been where, done what …

RegMed, stem, gene and cell therapy sector’s record over 5 sessions (of 40 covered companies):

  • Thursday closed NEGATIVE with 24 decliners, 14 advancers and 2 flats;
  • Wednesday closed NEGATIVE with 25 decliners, 14 advancers and 1 flat;
  • Tuesday closed NEGATIVE with 24 decliners, 15 advancers and 1 flat;
  • Monday closed POSITIVE with 17 decliners, 20 advancers and 3 flats;
  • Last Friday closed POSITIVE with 17 decliners, 21 advancers and 2 flat;

 

 

Henry’omics:

From last night’s newsletter, “…the sector got spooked by the market sell-off. Sector open negative, split to the upside at 11:30a.m., hit the skids at the mid-day falling further by 2 p.m. and closed negative. The story of the sector: how many of us have never worked so hard and invest to get so little in return!”

The sector will resume limping along … it is a little too early to say buy the dip.

The bottom line for now, sit tight - it's a downer and maybe by Monday, more probably Tuesday will sefine next week!

 

 

Today’s indications:

  • The iShares Nasdaq Biotechnology (IBB) is indicating a NEGATIVE -0.64% downside in Friday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) is NOT indicating in Friday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Friday’s pre-open;
  • The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.69% downside in Friday’s pre-open

 

 

Companies in my headlights:

AxoGen (AXGN) closed up +$4.75 to $33.95 with 1.3 M shares traded <3 month average = 293 K shares> after Wednesday’s -$2.00 to $29.20 with 478 K shares traded   after Tuesday’s +$1.70 to $31.20 after Monday’s +$0.55 to $29.50. As I had stated, AXGN is little too chart “toppy” for me even after Q4 and FY17 results which were not bad.  BUY to SELL;

Intrexon (XON) closed down -$0.12 to $12.90 yet after Q4 and FY17 results were issued the share in the aftermarket jumped +$0.58 or +4.50% - BUY;

Fate Therapeutics (FATE) closed up +$0.11 to $11.37 after Wednesday’s -$0.24 to $11.26 after Tuesday’s -$0.56 to $11.50 after Monday’s +$0.30 to $12.06 after last Friday’s +$1.18 to $11.76 with 1.05 M shares traded <3 month average =671.2 K shares traded>.  In thirteen (13) sessions, the stock has risen from $7.80 – a $7.41 or +65.1% premium – Maintaining SELL;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.